Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Senzime

4.77 SEK

-1.14 %

Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.14 %
-15.12 %
-26.16 %
-7.92 %
-13.27 %
-16.32 %
-58.80 %
-78.02 %
-19.62 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
749.92M SEK
Turnover
606.96K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18.2.
2026

Annual report '25

22.4.
2026

Interim report Q1'26

19.5.
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Press release11/19/2025, 7:09 AM

BioStock: Video from Senzime's presentation at BioStock Life Science Summit 2025

Senzime
Press release11/11/2025, 12:00 PM

Senzime to Present at Redeye and BioStock Investor Conferences

Senzime
Press release11/3/2025, 1:45 PM

Nomination Committee for Senzime Annual General Meeting 2026

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release10/30/2025, 1:49 PM

Redeye: Senzime (Q3 Review) - In the right direction

Senzime
Regulatory press release10/29/2025, 7:30 AM

SENZIME Q3 2025: STRONG GROWTH AND CLEAR STEPS TOWARDS PROFITABILITY

Senzime
Press release10/23/2025, 9:00 AM

Invitation to presentations of Senzime’s third quarter 2025 report

Senzime
Press release10/8/2025, 11:00 AM

Senzime launches EMGINE, the next-generation software suite advancing neuromuscular monitoring

Senzime
Press release10/3/2025, 12:30 PM

Senzime welcomes new European pediatric guidelines recommending EMG-based neuromuscular monitoring

Senzime
Press release9/17/2025, 11:15 AM

Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center

Senzime
Press release9/12/2025, 8:00 AM

Senzime to Present at Pareto Securities’ 16th Annual Healthcare Conference

Senzime
Press release9/12/2025, 7:00 AM

Senzime launches integration with Mindray patient monitors

Senzime
Press release9/9/2025, 9:00 AM

Senzime welcomes new Japanese guidelines on neuromuscular monitoring

Senzime
Press release9/8/2025, 11:15 AM

Senzime to Present at the European Growth Virtual Investor Conference on September 11

Senzime
Press release9/4/2025, 2:30 PM

Extensive Clinical and Competitive Evaluation Leads Major California University Hospital System to Standardize on Senzime’s TetraGraph System

Senzime
Press release9/4/2025, 9:06 AM

Redeye: Redeye Initiates Coverage of Senzime

Senzime
Press release8/5/2025, 9:00 AM

Senzime Secures TetraGraph Installations Across All Sites of World-Leading US Hospital System

Senzime
Regulatory press release7/31/2025, 1:00 PM

New number of shares and votes in Senzime AB (publ)

Senzime
Press release7/23/2025, 8:15 AM

Senzime’s TetraGraph System Receives Regulatory Approval in Mexico

Senzime
Press release7/22/2025, 3:19 PM

DNB Carnegie Access: Senzime: Scalability set to become more apparent in H2 – Q2 review

Senzime
Press release7/18/2025, 11:00 AM

DNB Carnegie Access: Senzime: Recording from earnings call Q2 (25)

Senzime
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.